ProMIS Neurosciences Appoints Seasoned Alzheimer’s and Neuroscience Executive Ivana Rubino, Ph.D., as Chief Commercial Officer
Key Highlights
- ➤Ivana Rubino appointed ProMIS chief commercial officer, effective October 5, 2026
- ➤PMN310 12-month PRECISE-AD topline results expected in Q1 2027
- ➤ProMIS grants Rubino 80,000-share inducement option at $9.37 exercise price
- ➤Rubino previously led Alzheimer’s medical strategy and launch readiness at Biogen
- ➤PMN310 Phase 1b study evaluates antibody in mild Alzheimer’s disease patients
Expert Statements
Neil Warma, President and Chief Executive Officer of ProMIS Neurosciences
“Ivana joins ProMIS at an important point in the evolution of PMN310 and our Alzheimer’s program”
Neil Warma, President and Chief Executive Officer of ProMIS Neurosciences
“She brings a rare combination of scientific depth and experience advancing major Alzheimer’s programs through launch readiness and commercialization at Biogen and Roche.”
Neil Warma, President and Chief Executive Officer of ProMIS Neurosciences
“Ivana’s broad neuroscience and strategic experience will help us build the capabilities needed for ProMIS’ next stage of growth, and her extensive background in Alzheimer’s disease will be particularly valuable as we move toward our 12-month PRECISE-AD topline readout of PMN310 in the first quarter of 2027.”
Ivana Rubino, Chief Commercial Officer of ProMIS Neurosciences
“Neuroscience has been at the center of my career, and I have had the privilege of working across several areas in which major scientific advances have transformed what is possible for patients.”
Ivana Rubino, Chief Commercial Officer of ProMIS Neurosciences
“Alzheimer’s disease is perhaps one of the clearest examples: although we have made significant progress, meaningful scientific, clinical and access challenges remain.”
Ivana Rubino, Chief Commercial Officer of ProMIS Neurosciences
“What attracted me to ProMIS was both the differentiated science behind PMN310 and the broader potential of the company’s approach to targeting toxic misfolded proteins.”
Ivana Rubino, Chief Commercial Officer of ProMIS Neurosciences
“If the clinical data in the ongoing Alzheimer’s trial continue to be supportive, PMN310 could represent an important next step in Alzheimer’s treatment.”
Ivana Rubino, Chief Commercial Officer of ProMIS Neurosciences
“I am excited to help translate the science into development and commercial strategies that can ultimately create meaningful value for patients, families and the neuroscience community.”
Former senior Biogen and Roche executive brings deep experience across Alzheimer’s clinical development, launch readiness, commercialization and global medical strategy
Appointment strengthens commercial and development leadership as PMN310 advances toward 12-month topline data expected in Q1 2027
Get started
Create a free account to read the full story.